GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » North China Pharmaceutical Co Ltd (SHSE:600812) » Definitions » Long-Term Capital Lease Obligation

North China Pharmaceutical Co (SHSE:600812) Long-Term Capital Lease Obligation : ¥257 Mil (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is North China Pharmaceutical Co Long-Term Capital Lease Obligation?

North China Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥257 Mil.

North China Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥362 Mil) to Dec. 2023 (¥299 Mil) and declined from Dec. 2023 (¥299 Mil) to Mar. 2024 (¥257 Mil).

North China Pharmaceutical Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (¥327 Mil) to Dec. 2022 (¥413 Mil) but then declined from Dec. 2022 (¥413 Mil) to Dec. 2023 (¥299 Mil).


North China Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for North China Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

North China Pharmaceutical Co Long-Term Capital Lease Obligation Chart

North China Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 280.69 326.74 413.39 299.16

North China Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360.08 394.89 362.11 299.16 256.57

North China Pharmaceutical Co  (SHSE:600812) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

North China Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of North China Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


North China Pharmaceutical Co (SHSE:600812) Business Description

Traded in Other Exchanges
N/A
Address
No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
Executives
Gao Ren Long senior management
Lian Fa Zhe Director

North China Pharmaceutical Co (SHSE:600812) Headlines

No Headlines